SeaStar Medical is trading 8.1% lower at $3.54, with no clear company-specific announcement identified to explain the October 13 move.

  • The broader market was nearly flat, offering no clear explanation; trading reversed sharply after the October 12 close at $3.85.
  • The FDA’s October 7 Breakthrough Device Designation and the October 5 warrant-exercise financing are earlier developments, not confirmed catalysts for the decline.
  • Current trading volume was not established by the sources reviewed.